Benjamin Adams

Eli Lilly and Company - Indianapolis / United States

Medical and Health Sciences / Neuroscience

AD Scientific Index ID: 4391887

-

Registration, Add Profile,
Premium Membership

Print Your Certificate

Benjamin Adams's MOST POPULAR ARTICLES

1-) LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLM Rorick-Kehn, JM Witkin, MA Statnick, EL Eberle, JH McKinzie, ...Neuropharmacology 77, 131-144, 20141292014

2-) Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent modelsRI Anderson, HC Becker, BL Adams, CD Jesudason, LM Rorick-KehnFrontiers in neuroscience 8, 33, 2014822014

3-) Altered performance characteristics in cognitive tasks: comparison of the albino ICR and CD1 mouse strainsB Adams, T Fitch, S Chaney, R GerlaiBehavioural brain research 133 (2), 351-361, 2002712002

4-) Performance deficits of mGluR8 knockout mice in learning tasks: the effects of null mutation and the background genotypeR Gerlai, B Adams, T Fitch, S Chaney, M BaezNeuropharmacology 43 (2), 235-249, 2002732002

5-) A novel, orally bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self‐administration and ethanol seeking in animal modelsLM Rorick‐Kehn, R Ciccocioppo, CJ Wong, JM Witkin, MA Martinez‐Grau, ...Alcoholism: Clinical and Experimental Research 40 (5), 945-954, 2016622016

ARTICLES

Add your articles